CIK 0001736730 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Camp4 Therapeutics Corp
Sign in to watch- Ticker
- CAMP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-651-8867
- Business address
- 100 TALCOTT AVENUE, SUITE 201, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $39,600
- in 1 filing
- Open-market sales, last 90 days
- $2,504,037
- in 4 filings
Net −$2,464,437. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-15 | Nashat Amir Director | Conversion | +1,250,061 | 1,250,061 | ||
| 2024-10-15 | Nashat Amir Director | Conversion | +87,448 | 87,448 | ||
| 2024-10-15 | Nashat Amir Director | Conversion | +353,718 | 1,603,779 | ||
| 2024-10-15 | Nashat Amir Director | Conversion | +24,745 | 112,193 | ||
| 2024-10-15 | Nashat Amir Director | Purchase | +909,090 | $11.00 | $10.0M | 909,090 |
| 2024-10-15 | Nashat Amir Director | Conversion · Series A Prime Preferred Stock | −14,020,475 | 0 | ||
| 2024-10-15 | Nashat Amir Director | Conversion · Series A Prime Preferred Stock | −980,829 | 0 | ||
| 2024-10-15 | Nashat Amir Director | Conversion · Series B Preferred Stock | −3,967,234 | 0 | ||
| 2024-10-15 | Nashat Amir Director | Conversion · Series B Preferred Stock | −277,536 | 0 | ||
| 2024-10-15 | Schwab Andrew J. Director | Conversion | +1,337,592 | 1,337,592 | ||
| 2024-10-15 | Schwab Andrew J. Director | Conversion | +378,463 | 1,716,055 | ||
| 2024-10-15 | Schwab Andrew J. Director | Conversion | +302,770 | 302,770 | ||
| 2024-10-15 | Schwab Andrew J. Director | Purchase | +909,090 | $11.00 | $10.0M | 2,625,145 |
| 2024-10-15 | Schwab Andrew J. Director | Conversion · Series A Prime Preferred Stock | −15,002,166 | 0 | ||
| 2024-10-15 | Schwab Andrew J. Director | Conversion · Series B Preferred Stock | −4,244,770 | 0 | ||
| 2024-10-15 | Schwab Andrew J. Director | Conversion · Series B Preferred Stock | −3,395,816 | 0 | ||
| 2024-10-15 | Holtzman Steven H Director | Conversion | +8,917 | 108,946 | ||
| 2024-10-15 | Holtzman Steven H Director | Conversion · Series A Prime Preferred Stock | −100,014 | 0 | ||
| 2024-10-15 | Young Richard A Director | Conversion | +8,917 | 154,859 | ||
| 2024-10-15 | Young Richard A Director | Conversion · Series A Prime Preferred Stock | −100,014 | 0 |
Page 5 of 6 · 111 trades